Related Experiment Video

Updated: Mar 18, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population

Ja Min Byun1, Jeong-Ok Lee1, Beodeul Kang1

  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Clinical Lymphoma, Myeloma & Leukemia
|July 5, 2016
PubMed

Insights

Elderly patients aged 75 and older with diffuse large B-cell lymphoma (DLBCL) experienced poorer treatment outcomes and higher mortality. An age cutoff of 75 years appears critical for predicting treatment success in Asian populations.

Area of Science:

  • Hematology
  • Oncology
  • Geriatrics

Background:

  • Real-world treatment outcomes for elderly patients with diffuse large B-cell lymphoma (DLBCL) in Asian populations require evaluation.
  • Defining an appropriate age cutoff for 'elderly' is crucial for understanding treatment tolerance and survival in DLBCL patients.

Purpose of the Study:

  • To evaluate real-world treatment outcomes in elderly Asian patients with DLBCL.
  • To determine a specific age cutoff for identifying elderly patients likely to experience adverse outcomes with standard immunochemotherapy.

Main Methods:

  • Retrospective analysis of 192 DLBCL patients over 60 years old treated with first-line immunochemotherapy.
  • Stratification of patients into four age groups: >60-64, 65-69, 70-74, and ≥75 years.
  • Analysis of treatment schedules, adverse events, survival rates, and treatment completion.

Main Results:

  • Patients aged ≥75 years showed significantly lower complete remission rates (51%) and higher treatment-related mortality (33.3%).
  • Older age (≥75 years) correlated with increased dose reductions (100%) and lower chemotherapy completion rates (51%).
  • Progression-free survival and overall survival were significantly poorer in patients aged ≥75 years (3-year rates 38.3% and 43.6%, respectively).
  • Multivariate analysis identified age ≥75 years and poor performance status as risk factors for overall survival.

Conclusions:

  • Elderly DLBCL patients under 75 years tolerated standard immunochemotherapy with acceptable survival.
  • An age of 75 years serves as a critical cutoff for predicting treatment outcomes in this Asian cohort.
  • Age ≥75 years is a significant risk factor for poorer survival in elderly DLBCL patients receiving immunochemotherapy.
Abstract

Keywords:
AsianDLBCLImmunochemotherapyOlder patientsPrognosis

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
344
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
324
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
795
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
310